The target of upadacitinib

Upadacitinib (Upadacitinib) is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes that transmit signals resulting from the interaction of cytokines or growth factor receptors on the cell membrane to influence cellular processes of hematopoietic and immune cell function. JAK enzymes transmit cytokine signals through their pairings (eg, JAK1/JAK2, JAK1/JAJ3, JAK1/TYK2, JAK2/JAK2, and JAK2/TYK2). In cell-free separase assays, upadatinib had greater inhibitory potency against JAK1 and JAK2 relative to JAK3 and TYK2. In signaling pathways, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which regulate intracellular activities, including gene expression. Upatinib regulates signaling pathways at JAKs points and prevents the phosphorylation and activation of STATs.